"Graystone Eye is an ophthalmology practice that was originally established in 1969. Our Mission is Preserving the Gift of Sight and Improving Lives – One Patient at a Time. Our practice is committed to providing the highest quality care and service in a timely and respectful manner. Our highly trained team of thirteen board certified ophthalmologists includes seven fellowship trained sub-specialists. Our practice is proudly focused on the following services: comprehensive eye care, cataracts, glaucoma, refractive procedures (iLASIK), corneal disorders, retina disorders, pediatric vision disorders, oculo-facial plastics (functional and aesthetic services), optical goods and contact lenses."

During the past decade, Graystone Eye conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Graystone Eye" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Graystone Eye" are "Diabetic Macular Edema" (3 trials), "Geographic Atrophy" (2 trials), "Branch Retinal Vein Occlusion" (1 trials), "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials) and "Macular Degeneration" (1 trials). Many other conditions were trialed in "Graystone Eye" in a lesser frequency.

Most popular intervention types in "Graystone Eye" are "Drug" (10 trials), "Other" (4 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (6 trials), "Faricimab" (5 trials), "Aflibercept" (3 trials), "APL-2" (1 trials) and "IONIS-FB-LRx" (1 trials). Other intervention names were less common.

The vast majority of trials in "Graystone Eye" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Graystone Eye". undefined are not yet recruiting, undefined are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Graystone Eye, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Graystone Eye, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".